# **Special Issue**

# Novel Nanoparticles for Targeted Delivery of Therapeutic Nucleic Acids

# Message from the Guest Editors

With the completion of the Human Genome project, there was great excitement about deciphering diseasecausing genes. Since then, a number of them has been identified, but still, there are only few diseases which have seen some therapeutic outcomes. Over the years, many scientists have worked in genetic therapies, and only recently has some success been realised. However, there is lots of progress and new tools (including ex vivo and in vivo models), and there is increased hype that efficient and safe targeted molecular therapies will become successful for several disorders. Here, we are going to highlight the recent advances in Nanomedicine (novel liposomal, polymeric or nanoparticle formulations, etc.) with the hope that they will play a significant role in both improving the quality of life and curing patients. This Special Issue welcomes original research papers and review articles dealing with the targeted therapeutic delivery of nucleic acids with novel nonviral nanocarriers.

# **Guest Editors**

Dr. Aristides D. Tagalakis

Department of Biology, Edge Hill University, Ormskirk L39 4QP, UK

Prof. Dr. Dimitrios A. Lamprou

School of Pharmacy, Queen's University Belfast, Belfast BT7 1NN, UK

Dr. Cynthia Yu-Wai-Man

King's College London, London SE1 7EH, UK

# Deadline for manuscript submissions

closed (31 July 2022)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/42105

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

### **Author Benefits**

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

# **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

